Key result
Momilactone B inhibited ketosis in an in vitro model by regulating the ANGPTL3-LPL pathway and suppressing HMGCS2 expression via increased STAT5b.
Why the study?
Does Momilactone B inhibit ketosis in an in vitro model?
Does Momilactone B inhibit ketosis in an in vitro model?
Momilactone B demonstrates anti-ketosis effects in vitro by regulating the ANGPTL3-LPL pathway and suppressing HMGCS2 via STAT5b.
Answers are grounded in this paper and cite their sources.
May attenuate ketosis in animal models; leaves open translation to human therapy.
Ketogenesis is the production of ketone bodies, which provide energy when the body lacks glucose. Under ketogenic conditions, the body switches from primarily carbohydrate to fat metabolism to maintain energy balance. However, accumulation of high levels of ketone bodies in the blood results in ketosis. Treating ketosis with natural substances is preferable, because they are unlikely to cause side-effects. Momilactone B is an active compound isolated from Korean rice. Based on previous studies, we hypothesized that momilactone B could inhibit ketosis. We constructed an in vitro ketosis model by glucose starvation. We used this model to test the anti-ketosis effects of momilactone B. A primary target for treating ketosis is angiopoietin-like-3 (ANGPTL3), which modulates lipoprotein metabolism by inhibiting lipoprotein lipase (LPL), a multifunctional enzyme that breaks down stored fat to produce triglycerides. We showed that momilactone B could regulate the ANGPTL3-LPL pathway. However, a strong anti-ketosis candidate drug should also inhibit ketogenesis. Ketogenesis can be suppressed by inhibiting the expression of 3-hydroxy-3-methylglutaryl-CoA synthase-2 (HMGCS2), a mitochondrial enzyme that converts acetyl-CoA to ketone bodies. We found that momilactone B suppressed the expression of HMGCS2 through the increased expression of STAT5b. We also elucidated the relationship of STAT5b to ANGPTL3 and LPL expression.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2016) studied Ketosis. Momilactone B was evaluated on Inhibition of ketosis via ANGPTL3-LPL pathway and HMGCS2 expression. Momilactone B inhibited ketosis in an in vitro model by regulating the ANGPTL3-LPL pathway and suppressing HMGCS2 expression via increased STAT5b.
Synapse has enriched 10 related papers. Consider them for comparative context: